Kenjiro Ono
Kenjiro Ono
Although α-synuclein protein (αS) undergoes aggregation from a monomer to assemblies, such as oligomers, protofibrils, and mature fibrils, the early intermediate aggregates, that is, oligomers, are considered to be the most toxic species ...
[Diagnosis of Multiple System Atrophy for Establishing Disease-modifying Therapies] [0.03%]
特发性运动障碍的诊断以求建立改变疾病进程的治疗措施
Takayoshi Shimohata
Takayoshi Shimohata
More accurate and early diagnoses of neurodegenerative diseases are required to establish disease-modifying therapies. Obtaining a clear diagnosis of multiple system atrophy (MSA), a neurodegenerative disease, can be challenging because MSA...
Kenya Nishioka,Nobutaka Hattori
Kenya Nishioka
To date, there have been several reports about the genes associated with familial Parkinson's disease. These genes are classified following the PARK nomenclature. The prevalence of these genes varies between countries. Moreover, each gene i...
Tomoyuki Miyamoto,Kyoko Numahata,Hideaki Ishido et al.
Tomoyuki Miyamoto et al.
REM sleep behavior disorder (RBD) can progress to Parkinson's disease, Lewy body dementia, or multiple system atrophy within 20 years of onset. Accurate diagnosis of RBD is therefore important for early intervention. The development of mark...
[Recovery of Forgotten Memories: Modulation of Memory Recall by Brain Histamine System] [0.03%]
遗忘记忆的复苏：脑组胺系统对记忆提取的调控作用
Hiroshi Nomura
Hiroshi Nomura
Even after memories fade they may persist latently in the brain. However, there are no clinically applicable methods for reactivating memory traces and promoting memory retrieval. In the brain histamine modulates learning and memory, sleep ...
Ichiro Nakashima
Ichiro Nakashima
Neuromyelitis optica spectrum disorder (NMOSD) is a disease related to anti-aquaporin-4 antibody. Since NMOSD was once considered a phenotype of multiple sclerosis, no approved drugs are available for its treatment. In Japan, the current st...
[Multiple Sclerosis] [0.03%]
[多发性硬化]
Kenji Kufukihara,Jin Nakahara
Kenji Kufukihara
Treatments for multiple sclerosis have improved dramatically over the last 20 years. These treatments help to reduce relapses and prevent progression of neurodegeneration and physical disability. Other clinical trials on remyelination thera...
[Current Status and Future Prospects of Therapeutic Development of Parkinson's Disease] [0.03%]
帕金森病的治疗研发现状与未来展望
Hideki Mochizuki
Hideki Mochizuki
There has been remarkable progress in the search for Parkinson's disease therapies. However, L-dopa replacement therapy remains the gold standard despite drawbacks that include wearing off and dyskinesias. Devices such as continuous infusio...
Akira Tamaoka
Akira Tamaoka
There is an urgent need for Alzheimer's disease (AD) treatments because of the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Unfortunately, there are few effective treatments for AD, and many drug deve...
Makoto Urushitani
Makoto Urushitani
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive muscle wasting and weakness. Riluzole was the sole drug available for treating ALS until 2015, when edaravone was approved as a new ...